相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vemurafenib Sensitivity Skin Reaction after Ipilimumab
James J. Harding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?
Robert O. Dillman et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2011)
Cancer Immunotherapy
Robert O. Dillman
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2011)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors in Metastatic Melanoma Patients Treated with Biochemotherapy and Maintenance Immunotherapy
David R. Minor et al.
ONCOLOGIST (2009)
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Systemic therapy for unresectable metastatic melanoma: Impact of biochemotherapy on long-term survival
Agop Y. Bedikian et al.
JOURNAL OF IMMUNOTOXICOLOGY (2008)
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma
R Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor-infiltrating lymphocytes and interleukin-2: Dose and schedules of administration in the treatment of metastatic cancer
R Dillman et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial
O Eton et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
